Abstract:Background Racial and ethnic minorities have disproportionately high hospitalization rates and mortality related to the novel coronavirus disease 2019 (Covid-19). There are comparatively scant data on race and ethnicity as determinants of infection risk. Methods We used a smartphone application (beginning March 24, 2020 in the United Kingdom [U.K.] and March 29, 2020 in the United States [U.S.]) to recruit 2,414,601 participants who reported their race/ethnicity through May 25, 2020 and employed logistic regression to determine the adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for a positive Covid-19 test among racial and ethnic groups. Results We documented 8,858 self-reported cases of Covid-19 among 2,259,841 non-Hispanic white; 79 among 9,615 Hispanic; 186 among 18,176 Black; 598 among 63,316 Asian; and 347 among 63,653 other racial minority participants. Compared with non-Hispanic white participants, the risk for a positive Covid-19 test was increased across racial minorities (aORs ranging from 1.24 to 3.51). After adjustment for socioeconomic indices and Covid-19 exposure risk factors, the associations (aOR [95% CI]) were attenuated but remained significant for Hispanic (1.58 [1.24-2.02]) and Black participants (2.56 [1.93-3.39]) in the U.S. and South Asian (1.52 [1.38-1.67]) and Middle Eastern participants (1.56 [1.25-1.95]) in the U.K. A higher risk of Covid-19 and seeking or receiving treatment was also observed for several racial/ethnic minority subgroups. Conclusions Our results demonstrate an increase in Covid-19 risk among racial and ethnic minorities not completely explained by other risk factors for Covid-19, comorbidities, and sociodemographic characteristics. Further research investigating these disparities are needed to inform public health measures. ### Competing Interest Statement TJW, RD, and JC are employees of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. DAD and ATC previously served as investigators on a clinical trial of diet and lifestyle using a separate mobile application that was supported by Zoe Global Ltd. Other authors have no conflict of interest to declare. ### Clinical Trial NCT04331509 ### Funding Statement Zoe provided in kind support for all aspects of building, running and supporting the app and service to users worldwide. LHN is supported by the American Gastroenterological Association Research Scholars Award. DAD is supported by the National Institute of Diabetes and Digestive and Kidney Diseases K01DK120742. ATC is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz supported MGH investigators (LHN, DAD, ADJ, CGG, WM, RSM, CHL, SK, ATC). King's College of London investigators (KAL, MNL, TV, MG, CHS, MJC, SO, CJS, TDS) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, and the Alzheimer's Society (AS-JF-17-011). MNL is supported by an NIHR Doctoral Fellowship (NIHR300159). CMA is supported by the NIDDK (K23 DK120899) and the Boston Children's Hospital Office of Faculty Development Career Development Award. The Multiethnic Cohort investigators (LRW. CAH, LLM) were supported by grant U01 CA164973. Sponsors had no role in study design, analysis, and interpretation of data, report writing, and the decision to submit for publication. The corresponding author had full access to data and the final responsibility to submit for publication. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Partners Human Research Committee (Protocol 2020P000909), King's College London Ethics Committee (REMAS ID 18210, LRS-19/20-18210) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Data collected in the app are being shared with other health researchers through the NHS-funded Health Data Research UK (HDRUK)/SAIL consortium, housed in the UK Secure e-Research Platform (UKSeRP) in Swansea. Anonymized data collected by the Covid Symptom Study app can be shared with bonafide researchers via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6). US investigators are encouraged to coordinate data requests through the COPE Consortium (www.monganinstitute.org/cope-consortium). Data updates can be found at https://covid.joinzoe.com. <https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6> <https://www.monganinstitute.org/cope-consortium> <https://covid.joinzoe.com>

Cancer and Race: Two Important Risk Factors for COVID-19 Incidence As Captured by the COVID Symptom Study Real-Time Epidemiology Tool.

Abstract S09-01: Cancer and Race: Two Important Risk Factors for COVID-19 Incidence As Captured by the COVID Symptom Study Real-Time Epidemiology Tool

Cancer and Risk ofCOVID-19 Through a General Community Survey

Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection

Cancer and risk of COVID-19 through a general community survey

Characterizing cancer and COVID-19 outcomes using electronic health records

Racial and ethnic determinants of Covid-19 risk

The COVID‐19 pandemic and associated declines in cancer incidence by race/ethnicity and census‐tract level SES, rurality, and persistent poverty status

Race, ethnicity, community-level socioeconomic factors, and risk of COVID-19 in the United States and the United Kingdom

Racial Disparities in Young-Onset Patients with Colorectal, Breast and Testicular Cancer

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Racial and ethnic disparities in lifestyle changes during the COVID-19 pandemic: Exploring the socioeconomic and psychosocial mechanisms.

Abstract CT406: Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multi-Center Study During the COVID-19 Outbreak

Cancer and COVID-19 Susceptibility and Severity: A Two-Sample Mendelian Randomization and Bioinformatic Analysis

The Impact of COVID-19 on Cancer Screening and Treatment in Older Adults: The Multiethnic Cohort Study

Racial and socioeconomic disparities in telemedicine use among US patients initiating cancer treatment during the COVID-19 pandemic.

Disparities in cancer stage shifts associated with the COVID-19 pandemic in California, 2020-2021

The Mental Health Burden of Racial and Ethnic Minorities During the COVID-19 Pandemic.

Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer

Sociodemographic Inequities in Telemedicine Use Among US Patients Initiating Treatment in Community Cancer Centers During the Ongoing COVID-19 Pandemic, 2020-2022

Abstract B090: Assessing the relationship between family history of cancer and self-perceived cancer risk among Black adults in the United States